## Eleni Bekiari

## List of Publications by Citations

Source: https://exaly.com/author-pdf/2382702/eleni-bekiari-publications-by-citations.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

38 1,459 14 49 h-index g-index citations papers 1,926 4.67 52 5.5 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
49	Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. <i>Annals of Internal Medicine</i> , <b>2013</b> , 159, 262-74	8	596
48	Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. <i>BMJ, The</i> , <b>2018</b> , 361, k1310	5.9	192
47	Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. <i>Annals of Internal Medicine</i> , <b>2020</b> , 173, 278-286	8	70
46	Performance of Baveno VI and Expanded Baveno VI Criteria for Excluding High-Risk Varices in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 1744-1755.e11	6.9	49
45	Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 2255-2263	6.7	39
44	Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. <i>Endocrine</i> , <b>2016</b> , 52, 458-80	4	34
43	Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. <i>Annals of Internal Medicine</i> , <b>2018</b> , 169, 165-174	8	27
42	Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 335-345	6.7	27
41	Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , <b>2015</b> , 6, 61-7	4.5	24
40	A simple plaster for screening for diabetic neuropathy: a diagnostic test accuracy systematic review and meta-analysis. <i>Metabolism: Clinical and Experimental</i> , <b>2014</b> , 63, 584-92	12.7	24
39	Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 188-193	6.7	20
38	Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis. <i>Annals of Gastroenterology</i> , <b>2018</b> , 31, 572-582	2.2	17
37	Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2017</b> , 18, 843-851	4	14
36	Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 1857-1868	6.7	14
35	Arterial stiffness and peripheral arterial disease in patients with systemic lupus erythematosus. <i>Rheumatology International</i> , <b>2017</b> , 37, 293-298	3.6	14
34	Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications. <i>Therapeutic Advances in Drug Safety</i> , <b>2016</b> , 7, 36-8	3.5	12
33	GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes Research and Clinical Practice</i> , <b>2021</b> , 174, 108737	7.4	12

32	Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysis. <i>Endocrine</i> , <b>2017</b> , 56, 485-494	4	11
31	Eosinophilic pneumonia associated with heroin inhalation: a case report. <i>Wiener Klinische Wochenschrift</i> , <b>2008</b> , 120, 178-80	2.3	10
30	Hepatocellular carcinoma occurrence in DAA-treated hepatitis C virus patients: Correlated or incidental? A brief review. <i>World Journal of Hepatology</i> , <b>2018</b> , 10, 595-602	3.4	10
29	Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 2116-2124	6.7	9
28	Insulin sensitivity assessment with euglycemic insulin clamp in adult beta-thalassaemia major patients. <i>European Journal of Haematology</i> , <b>2007</b> , 79, 526-30	3.8	8
27	Effect of epinephrine and insulin resistance on human monocytes obtained from lean and obese healthy participants: a pilot study. <i>Angiology</i> , <b>2011</b> , 62, 38-45	2.1	7
26	Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysis. <i>European Journal of Haematology</i> , <b>2017</b> , 98, 563-568	3.8	6
25	Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 822-831	6.7	6
24	Intravenous Immunoglobulin for Patients With Alzheimer Disease: A Systematic Review and Meta-Analysis. <i>American Journal of Alzheimer Disease and Other Dementias</i> , <b>2019</b> , 34, 281-289	2.5	5
23	Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy. <i>Core Evidence</i> , <b>2017</b> , 12, 1-10	4.9	5
22	Safety and efficacy of 4 years of deferasirox treatment for sickle cell disease patients. <i>Hemoglobin</i> , <b>2013</b> , 37, 94-100	0.6	5
21	Patients Vand Clinicians VPreferences on Outcomes and Medication Attributes for Type 2 Diabetes: a Mixed-Methods Study. <i>Journal of General Internal Medicine</i> , <b>2020</b> , 1	4	5
20	Antigen-based immunotherapies do not prevent progression of recent-onset autoimmune diabetes: a systematic review and meta-analysis. <i>Endocrine</i> , <b>2016</b> , 54, 620-633	4	4
19	Effect of glucose and insulin on oxidized low-density lipoprotein phagocytosis by human monocytes: a pilot study. <i>Angiology</i> , <b>2011</b> , 62, 163-6	2.1	4
18	Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2019</b> , 12, 2549-2557	3.4	4
17	GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials. <i>Diabetes Research and Clinical Practice</i> , <b>2021</b> , 177, 108921	7.4	3
16	Canagliflozin for Type 2 diabetes: an up-to-date evidence summary. <i>Diabetes Management</i> , <b>2015</b> , 5, 119	9-1)25	2
15	Meta-analysis of artificial pancreas trials: methodological considerations. <i>Lancet Diabetes and Endocrinology,the</i> , <b>2017</b> , 5, 685	18.1	2

14	Sotagliflozin for patients with type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2022</b> , 24, 106-114	6.7	2
13	Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia. <i>Annals of Internal Medicine</i> , <b>2015</b> , 163, 241	8	1
12	Erythrocytosis Secondary to Testosterone Therapy in a Male with Cryptorchidism: A Case Report. <i>International Journal of Gerontology</i> , <b>2012</b> , 6, 290-291		1
11	Some glucose-lowering drugs reduce risk for major adverse cardiac events. <i>Annals of Internal Medicine</i> , <b>2020</b> , 173, JC9	8	1
10	Ultra-rapid-acting insulins for adults with diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 2395-2401	6.7	1
9	Monitoring and Managing Cardiovascular Risk in Immune Mediated Inflammatory Diseases <i>Journal of Inflammation Research</i> , <b>2021</b> , 14, 6893-6906	4.8	1
8	Add-on interventions for the prevention of recurrent Clostridioides Difficile infection: A systematic review and network meta-analysis. <i>Anaerobe</i> , <b>2021</b> , 71, 102441	2.8	O
7	In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly exenatide ER. <i>Annals of Internal Medicine</i> , <b>2018</b> , 168, JC46	8	
6	Hemosiderosis and diabetes mellitus in an untransfused patient with hemoglobin H disease and H63D homozygous hereditary hemochromatosis. <i>Diabetes Research and Clinical Practice</i> , <b>2007</b> , 76, 468-	97.4	
5	In type 2 diabetes, SGLT2 inhibitors were linked to diabetic ketoacidosis vs. DPP-4 inhibitors. <i>Annals of Internal Medicine</i> , <b>2020</b> , 173, JC70	8	
4	KDIGO made 12 recommendations for managing diabetes with CKD. <i>Annals of Internal Medicine</i> , <b>2021</b> , 174, JC26	8	
3	Most add-on therapies to metformin have similar effects on HbA1c. <i>Evidence-Based Medicine</i> , <b>2016</b> , 21, 223		
2	Sodium-Glucose Cotransporter 2 Inhibition and Cardiovascular Risk. <i>Current Cardiovascular Risk Reports</i> , <b>2016</b> , 10, 1	0.9	
1	Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes. <i>Annals of Internal Medicine</i> , <b>2021</b> , 174, 141	8	